Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD of Niagen Bioscience, Inc. from 2013 to Q3 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Niagen Bioscience, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2013 to Q3 2025.
- Niagen Bioscience, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2025 was $4.8M, a 156% increase year-over-year.
- Niagen Bioscience, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending September 30, 2025 was $21.3M.
- Niagen Bioscience, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $8.86M.
- Niagen Bioscience, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$4.94M.
- Niagen Bioscience, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2017 was -$16.5M, a 365% decline from 2016.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)